Biosimilars In Malaysia: Regulations, Clinical Trials, And Adverse Events

Biological therapies have transformed the treatment landscape for chronic and life-threatening diseases, including cancer, autoimmune disorders, and diabetes. However, the excessive cost of biologics continues to challenge healthcare systems globally.

Biosimilars, highly similar versions of approved reference biologics offer a cost-effective and accessible alternative, without compromise on quality, safety, or efficacy. In Malaysia, the adoption of biosimilars is steadily increasing, driven by regulatory support and growing healthcare demand.

Since the approval of the first biosimilar (somatropin) in 2010, Malaysia has developed a robust regulatory and clinical framework to support biosimilar development, approval, and post-market monitoring.

Regulatory Framework for Biosimilars in Malaysia

1. Role of NPRA (National Pharmaceutical Regulatory Agency)

The NPRA, under the Ministry of Health Malaysia, is responsible for:

• Evaluation and approval of biosimilars 
• Regulatory compliance enforcement 
• Pharmacovigilance oversight 

Malaysia introduced biosimilar guidelines in 2008, aligning with global standards set by:

• WHO (World Health Organization) 
• EMA (European Medicines Agency) 
• FDA (U.S. Food and Drug Administration) 

2. Stepwise Biosimilar Development Approach

Malaysia follows a comparability-based regulatory pathway:

3. Key Regulatory Requirements

• Demonstration of high similarity to reference biologic 
• Comparative clinical trials 
• Robust Risk Management Plan (RMP) 
• Post-marketing safety monitoring 

Biosimilar Approvals and Market Landscape

• Over 20+ biosimilars approved in Malaysia 
• Major therapeutic areas: 
  • Diabetes (insulin products) 
  • Oncology (monoclonal antibodies) 
  • Hematology (erythropoietin) 

Market Challenges

Clinical Trials for Biosimilars in Malaysia

Clinical trials play a critical role in establishing bio similarity in efficacy, safety, and immunogenicity.

Key Clinical Trial Requirements

• Comparative Phase I (PK/PD studies) 
• Phase III efficacy and safety trials 
• Immunogenicity assessment 

Malaysia as a Clinical Research Hub

Malaysia has emerged as a preferred destination for biosimilar clinical trials due to:

• Strong regulatory framework 
• Skilled investigators and healthcare infrastructure 
• Government support for clinical research 

Clinical Trial Ecosystem

Adverse Events and Pharmacovigilance

Importance of Safety Monitoring

Biosimilars, like biologics, may trigger:

• Immunogenic responses 
• Hypersensitivity reactions 
• Injection-site reactions 

Adverse Event Data Insights

• Total reported AEs: ~499 cases 
• Serious cases: ~8–9% 
• Most common reactions: 
  • Skin and subcutaneous disorders (~33%) 

No fatal outcomes reported, indicating a favorable safety profile.

Pharmacovigilance Framework in Malaysia

Best Practices in Biosimilar Safety Monitoring

• Implementation of Risk Management Plans (RMPs) 
• Continuous post-marketing surveillance 
• Real-world evidence (RWE) collection 
• Healthcare professional engagement 

Emerging Trends in Biosimilars

• Expansion of biosimilar monoclonal antibodies 
• Increased use of real-world evidence (RWE) 
• Adoption of digital pharmacovigilance systems 
• Growth in local biosimilar manufacturing 
• Regulatory convergence across ASEAN 

Challenges in Biosimilar Adoption

Outlook for Biosimilars in Malaysia

The biosimilar market in Malaysia is expected to grow due to:

• Increasing demand for affordable biologics 
• Government initiatives supporting healthcare access. 
• Expansion of biosimilar pipelines 
• Strengthening regulatory frameworks 

How Maven Regulatory Solutions Supports Biosimilar Development

1. Regulatory Strategy & NPRA Compliance

• Biosimilar registration support 
• Dossier preparation (CTD format) 
• Regulatory pathway optimization 

2. Clinical & Non-Clinical Support

• Clinical trial strategy and design 
• PK/PD and immunogenicity evaluation 
• CRO coordination 

3. Pharmacovigilance & Risk Management

• RMP development 
• Adverse event monitoring systems 
• Signal detection and reporting. 

4. Toxicological & Scientific Assessment

• Biological product safety evaluation 
• Comparative analytical assessments 
• Risk-based justification. 

Conclusion

Biosimilars represent a transformational opportunity to improve access to affordable biological therapies in Malaysia. With:

• A strong regulatory framework 
• Increasing clinical research capabilities 
• Robust pharmacovigilance systems 

Malaysia is well-positioned to become a key player in the biosimilar landscape.

To fully realize this potential, stakeholders must address:

• Market access challenges 
• Awareness and education gaps 
• Regulatory and pricing barriers 

FAQs

1. What are biosimilars?

Biosimilars are highly similar versions of approved biologic drugs with no clinically meaningful differences in safety or efficacy.

2. Who regulates biosimilars in Malaysia?

The National Pharmaceutical Regulatory Agency (NPRA).

3. Are clinical trials required for biosimilars?

Yes, comparative clinical trials are essential to demonstrate bio similarity.

4. What is pharmacovigilance in biosimilars?

It involves monitoring and evaluating adverse drug reactions after market approval.

5. Are biosimilars safe?

Yes, when approved, they meet strict regulatory standards for safety, efficacy, and quality.